Business Wire

MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients With Plaque Psoriasis Treated With MC2-01 PADTM Cream

Share

MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD™ Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet® gel (marketed in the US as Taclonex® Topical Suspension).

“Completion of patient enrollment in this EU Phase 3 registration study marks yet another significant and timely accomplishment for the MC2-01 PAD™ Cream global development program in plaque psoriasis following our successful US Phase 3 head-to-head study in 2018,” stated Jesper J. Lange, CEO & President of MC2 Therapeutics. He added: “Our efforts in both EU and US demonstrate that we are committed to build leadership in topical therapies for patients with chronic inflammatory conditions. Our proprietary PAD™ Technology enables us to develop a new standard of topical therapies that combine fast and effective relief of symptoms with a unique moisturizing and cosmetic feel that we believe will significantly upgrade the patient experience and convenience in daily routines.”

About the MC2-01 PAD™ Cream Phase 3 Study

The study is a Phase 3, randomized, multicenter, investigator-blind, parallel-group study to evaluate the efficacy and safety of MC2-01 PAD™ Cream in subjects with plaque psoriasis compared to MC2-01 vehicle and Daivobet® gel. Subjects apply study medication topically once daily for up to 8 weeks. The primary objective is to show therapeutic superiority of MC2-01 PAD™ Cream to the active comparator, as well as to characterize the safety profile of MC2-01 PAD™ Cream in subjects with plaque psoriasis. The primary efficacy endpoint is percentage change from baseline in mPASI on the body at Week 8. The study enrolled 490 patients in 32 centres in Europe.

About MC2 Therapeutics A/S

MC2 Therapeutics A/S is a privately held late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a unique oil-in-water dispersion – MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.

For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com

Contact information

MC2 Therapeutics A/S
Lonni Goltermann, EA to the CEO // +45 2018 1111 or log@mc2therapeutics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Forecast: Resurgence of COVID-19 Could Cause Global Economic Depression4.6.2020 15:00:00 EESTPress release

According to the Moody’s Analytics baseline economic forecast, real global GDP will fall by 4.5% this year as a result of COVID-19. Our base case for the US suggests that it will take until mid-decade for the economy to return to full-employment. Mark Zandi, Chief Economist at Moody’s Analytics, describes the outlook in a new paper, Handicapping the Paths for the Pandemic Economy . “COVID-19 has caused massive damage to the global economy. Quickly reopening economies will boost growth by unleashing pent-up demand, but will also raise the specter of a re-intensification of COVID-19 and another economic downdraft, which could lead to a worldwide depression. We construct our economic forecasts to help market participants navigate this daunting uncertainty and make better decisions,” said Mr. Zandi. The Moody’s Analytics baseline economic forecast represents our view of the most likely trajectory for the global economy. The baseline forecast is part of a set of 12 forecast scenarios, updat

Vertex Enhances Integrated Tax Solution for SAP® Ariba®4.6.2020 14:13:00 EESTPress release

Vertex, Inc., a leading provider of tax technology and services, announced enhancements to its solutions integration with SAP® Ariba® Buying and Invoicing, providing customers with timely, advanced tax insights within their procurement and supply chain processes. Vertex launched an SAP Ariba Tax API and the Vertex Indirect Tax for Procurement with SAP Ariba app extension in 2018, enabling companies to obtain tax calculations from within SAP Ariba Buying and Invoicing, while also supporting the requisition and invoice reconciliation phases of the tax process. This integration with SAP Ariba solutions helps calculate tax at the purchase requisition, invoice reconciliation and final tax determination phases, carrying tax from the purchase requisition to the purchase order. The integrated solution is now enhanced to distinguish between vendor charged, buyer payable, self-assessed and value-added reverse charge taxes, as well as multiple levels of jurisdictions. SAP Ariba solutions provide

Moody’s Analytics Tops 14 International Categories in FocusEconomics Analyst Forecast Awards4.6.2020 14:00:00 EESTPress release

Moody’s Analytics, a global provider of financial intelligence, ranks #1 in 14 international categories in the 2020 FocusEconomics Analyst Forecast Awards. These awards include #1 Best Overall Forecaster – Hong Kong, plus the top ranking in five other forecast categories across 12 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005200/en/ #1 Best Overall Forecaster – Hong Kong #1 Interest Rate Forecaster – Austria #1 Interest Rate Forecaster – Italy #1 Interest Rate Forecaster – Portugal #1 Interest Rate Forecaster – Bahrain #1 Inflation Forecaster – Belgium #1 Inflation Forecaster – Malaysia #1 Current Account Forecaster – Brazil #1 Current Account Forecaster – Uruguay #1 Fiscal Balance Forecaster – Croatia #1 Fiscal Balance Forecaster – Peru #1 GDP Forecaster – Malaysia #1 GDP Forecaster – Slovenia #1 GDP Forecaster – Tunisia We also took second or third place in an additional 29 categories including: #2 Be

Temenos Recognized as the Only Global Power Seller in the 2020 Deal Survey, With More Than Double the New Named Deals of the Next Banking Platform4.6.2020 12:30:00 EESTPress release

Temenos (SIX: TEMN), the banking software company, has been listed as the industry’s only ‘Global Power Seller’ in Forrester’s prestigious Global Banking Platform Deals Survey 2020 with 30% increase in new named deals. Temenos landed more new global banking deals than any other provider in 2019, as stated in the Forrester report. Temenos was also named ‘Top Global Player’ in the survey, based on combined deals, which represent a vendor’s ability to enhance its market position and keep creating value for its existing customers. Forrester reconfirmed Temenos’ status as a ‘Top Global Player’ for the 8th consecutive year. This ranking recognizes platforms with over 150 combined deals (new names and extended deals with existing customers) in more than five regions. With 177 deals signed with new and existing customers, Temenos maintained its position at the forefront of the table. Temenos also retains its position as a ‘Global Power Seller’, the highest status in the vendor pyramid for new

Deenova Continues its Pharmacy Automation Market Expansion with 7 Robots Sales in France4.6.2020 12:03:00 EESTPress release

Deenova reported today that its recent market momentum in 2020 relentlessly extended to France, with 7 new robots contracts received by Deenova from Vinci Construction and the French Ministry of Economy and Finance, Groupe Hospitalier de Haute-Saône in Vesoul, and Adef Résidences Association Hopital Nord 92 Villeneuve-la-Garenne in the greater Paris area. Loïc Bessin, Managing Director of Deenova and Ecodex in France, stated: “I’m delighted to advance Deenova’s undeniable and dominant international expansion in 2020, this time in France, with our Deenova’s centralised unit-dose robots and related products and consumables. I’m very proud for our French team to continue Deenova’s unparalleled success in pioneering the pharmacy unit-dose traceability sector, already started in Italy, Malta, and the United Kingdom. Our corporate DNA ensures maximum traceability of medicines, total security of unit-doses, and greater consumption efficiency resulting in a significant reduction in pharmacy ex

WORTH Partnership Project: Organic Chairs, Fish Leather and Interactive Clothing4.6.2020 10:00:00 EESTPress release

Organic chairs that are “nourished” to reach desired shape, glassware derived from special waste, new alternative materials derived from fish to replace animal leather, illustrated children’s clothing that are enriched with new content through augmented reality and app interactions: Recycling, sustainability and the advanced use of technology attested that the mantra is always at the heart of creativity and innovative experiences by new generation European designers. All designers, under the Worth Partnership Project, an initiative financed by the European Union COSME programme, will be online from the 15th to 21st of June to showcase their projects and their concepts behind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005050/en/ Worth Partnership Project_"Lucid", organic chair "nourished” to reach desired shape (Photo: WORTH Partnership Project) 7 video conferences for 7 topics in 7 days: to discover the Worth Part

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom